We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Lower Patient Days Affect Tenet Healthcare's Q4 Earnings?
Read MoreHide Full Article
Key Takeaways
THC is expected to post Q4 EPS of $4.08, up 18.6% year over year, on revenues projected to rise 7.5%.
THC's hospital patient days and average length of stay are both projected to fall sharply in Q4.
THC's Ambulatory Care segment is set for strong growth, with operating revenues expected to rise.
Hospital company Tenet Healthcare Corporation (THC - Free Report) is set to report fourth-quarter 2025 results on Feb. 11, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $4.08 per shareon revenues of $5.45 billion.
The fourth-quarter earnings estimate has increased 3 cents over the past 60 days. The bottom-line projection indicates a year-over-year increase of 18.6%. Also, the Zacks Consensus Estimate for quarterly revenues suggests year-over-year growth of 7.5%.
Image Source: Zacks Investment Research
For full-year 2025, the Zacks Consensus Estimate for Tenet Healthcare’s revenues is pegged at $21.26 billion, implying a rise of 2.9% year over year. The consensus mark for 2025 earnings per share is pegged at $16.15, indicating a jump of 35.9% on a year-over-year basis.
Tenet Healthcare beat the consensus estimate for earnings in each of the trailing four quarters, with the average surprise being 27.6%, as you can see below.
Tenet Healthcare Corporation Price and EPS Surprise
However, our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That’s not the case here.
THC has an Earnings ESP of +2.72% and carries a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
The Zacks Consensus Estimate for adjusted patient admissions in total hospital operations suggests 3.9% year-over-year growth. Also, on the same hospital basis, the consensus estimate for adjusted patient admissions indicates a 2.7% increase from a year ago.
Meanwhile, the Ambulatory Care business is likely to have gained from better patient volumes, new service line growth and buyouts. Our model estimate for the Ambulatory Care segment’s operating revenues suggests 8.4% growth from the prior-year quarter’s figure, whereas the consensus estimate indicates a 9.8% increase. Higher patient service revenues are likely to have provided a boost in the fourth quarter. The Zacks Consensus Estimate for adjusted EBITDA from Ambulatory Care operations suggests 9% year-over-year growth.
The Zacks Consensus Estimate for Hospital Operations and Services revenues for the fourth quarter is pegged at $4.07 billion, indicating a 6.9% increase from the year-ago period. The consensus mark for net patient revenues per adjusted admission in the fourth quarter signals a 4.5% year-over-year increase.
The above-mentioned factors are likely to have benefited THC’s results in the quarter under review, positioning it for year-over-year growth. However, both the consensus estimate and our model estimate suggest that fourth-quarter total hospital patient days have decreased 6.5% year over year.
Both the Zacks Consensus Estimate and our model estimate for the average length of stay in total hospital indicate an 8.8% decrease from a year ago. Also, with increased utilization, costs are expected to have increased in the fourth quarter, making an earnings beat uncertain.
How Other Medical Companies Performed?
Companies belonging to the broader Medical space, like HCA Healthcare, Inc. (HCA - Free Report) , The Ensign Group, Inc. (ENSG - Free Report) and Encompass Health Corporation (EHC - Free Report) , have also reported results for the December quarter. Here’s how they have performed:
HCA Healthcare reported fourth-quarter 2025 adjusted EPS of $8.01, which outpaced the Zacks Consensus Estimate by 8.8% on the back of strong admissions. Modest gains in emergency room visits and a rise in revenue per equivalent admission also supported performance. However, the upside was partly offset by HCA Healthcare’s elevated operating expenses.
Ensign reported a fourth-quarter 2025 adjusted EPS of $1.82, which beat the Zacks Consensus Estimate by 4%, supported by improved occupancy rates, higher patient days and higher skilled service performance. The positives were partly offset by Ensign’s higher expenses.
Encompass Health reported fourth-quarter 2025 adjusted EPS of $1.46, which beat the Zacks Consensus Estimate by 13.2%,driven by higher net revenue per discharge and increased discharges, with growth coming from both inpatient and other revenues. At the same time, rising operating expenses partially offset these positives.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Will Lower Patient Days Affect Tenet Healthcare's Q4 Earnings?
Key Takeaways
Hospital company Tenet Healthcare Corporation (THC - Free Report) is set to report fourth-quarter 2025 results on Feb. 11, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $4.08 per shareon revenues of $5.45 billion.
The fourth-quarter earnings estimate has increased 3 cents over the past 60 days. The bottom-line projection indicates a year-over-year increase of 18.6%. Also, the Zacks Consensus Estimate for quarterly revenues suggests year-over-year growth of 7.5%.
For full-year 2025, the Zacks Consensus Estimate for Tenet Healthcare’s revenues is pegged at $21.26 billion, implying a rise of 2.9% year over year. The consensus mark for 2025 earnings per share is pegged at $16.15, indicating a jump of 35.9% on a year-over-year basis.
Tenet Healthcare beat the consensus estimate for earnings in each of the trailing four quarters, with the average surprise being 27.6%, as you can see below.
Tenet Healthcare Corporation Price and EPS Surprise
Tenet Healthcare Corporation price-eps-surprise | Tenet Healthcare Corporation Quote
Q4 Earnings Whispers for THC
However, our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That’s not the case here.
THC has an Earnings ESP of +2.72% and carries a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
You can see the complete list of today’s Zacks #1 Rank stocks here.
What’s Shaping THC’s Q4 Results?
The Zacks Consensus Estimate for adjusted patient admissions in total hospital operations suggests 3.9% year-over-year growth. Also, on the same hospital basis, the consensus estimate for adjusted patient admissions indicates a 2.7% increase from a year ago.
Meanwhile, the Ambulatory Care business is likely to have gained from better patient volumes, new service line growth and buyouts. Our model estimate for the Ambulatory Care segment’s operating revenues suggests 8.4% growth from the prior-year quarter’s figure, whereas the consensus estimate indicates a 9.8% increase. Higher patient service revenues are likely to have provided a boost in the fourth quarter. The Zacks Consensus Estimate for adjusted EBITDA from Ambulatory Care operations suggests 9% year-over-year growth.
The Zacks Consensus Estimate for Hospital Operations and Services revenues for the fourth quarter is pegged at $4.07 billion, indicating a 6.9% increase from the year-ago period. The consensus mark for net patient revenues per adjusted admission in the fourth quarter signals a 4.5% year-over-year increase.
The above-mentioned factors are likely to have benefited THC’s results in the quarter under review, positioning it for year-over-year growth. However, both the consensus estimate and our model estimate suggest that fourth-quarter total hospital patient days have decreased 6.5% year over year.
Both the Zacks Consensus Estimate and our model estimate for the average length of stay in total hospital indicate an 8.8% decrease from a year ago. Also, with increased utilization, costs are expected to have increased in the fourth quarter, making an earnings beat uncertain.
How Other Medical Companies Performed?
Companies belonging to the broader Medical space, like HCA Healthcare, Inc. (HCA - Free Report) , The Ensign Group, Inc. (ENSG - Free Report) and Encompass Health Corporation (EHC - Free Report) , have also reported results for the December quarter. Here’s how they have performed:
HCA Healthcare reported fourth-quarter 2025 adjusted EPS of $8.01, which outpaced the Zacks Consensus Estimate by 8.8% on the back of strong admissions. Modest gains in emergency room visits and a rise in revenue per equivalent admission also supported performance. However, the upside was partly offset by HCA Healthcare’s elevated operating expenses.
Ensign reported a fourth-quarter 2025 adjusted EPS of $1.82, which beat the Zacks Consensus Estimate by 4%, supported by improved occupancy rates, higher patient days and higher skilled service performance. The positives were partly offset by Ensign’s higher expenses.
Encompass Health reported fourth-quarter 2025 adjusted EPS of $1.46, which beat the Zacks Consensus Estimate by 13.2%,driven by higher net revenue per discharge and increased discharges, with growth coming from both inpatient and other revenues. At the same time, rising operating expenses partially offset these positives.